Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
|Articles|April 7, 2022
Daily Medication Pearl: Valbenazine (Ingrezza)
Author(s)Saro Arakelians, PharmD
Valbenazine (Ingrezza) is indicated for the treatment of adults with tardive dyskinesia.
Advertisement
Medication Pearl of the Day: Valbenazine (Ingrezza)
Indication: Valbenazine (Ingrezza) is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia.
Insight:
- Dosing:The initial dose is 40 mg once daily. After 1 week, increase the dose to the recommended dose of 80 mg once daily.
- Dosage forms: Capsules 40 mg.
- Adverse events: Most common adverse reaction (≥5% and twice the rate of placebo) is somnolence.
- Mechanism of action: The mechanism of action of valbenazine in the treatment of tardive dyskinesia is unknown but is thought to be mediated through the reversible inhibition of VMAT2, a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release.
- Manufacturer: Neurocrine Biosciences
Advertisement
Related to this article
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ramantamig's 93.6% ORR and Outpatient CRS Control
2
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
After 180 Years, Multiple Myeloma Gets a Definition of Cure
5